0620/24SCR019-18/R10
Media Highlights
From the 2024 ASCO® Annual Meeting
4
Media Outlet Article / Coverage
ASCO Daily News Early Data Support the Safety and Efficacy of a Novel
Engineered Protein for Advanced Cutaneous Melanoma
eCancer 3 Year Follow-Up Shows Durable Long-Term RFS and DMFS Benefit
with mRNA-4157 Plus Pembrolizumab in Resected Melanoma
eCancer PD-1–Refractory Advanced Melanoma: How Do We Get to
The Finish Line?
eCancer Highlights in Melanoma from ASCO 2024
VJ Oncology Evaluating JZP898, an IFN-α and Pembrolizumab in
Advanced Solid Tumors
VJ Oncology ASCO 2024 | Melanoma Trials at ASCO 2024: KEYMAKER-
U02A, IMC-F106 and SC-682
VuMedi ASCO® 2024 Summary: "PD-1-Refractory Advanced
Melanoma - Getting to the Finish Line"
Meredith McKean, MD, MPH
SCRI
Media Outlet Article / Coverage
MedPage Today Are T-DXd Results in HER2-Low/Ultralow Breast Cancer Practice-
Changing?
OncLive Anthracycline Plus Chemo Associated With Improved RFS in MP
High-2–Risk, HR+/HER2– Early Breast Cancer
Joyce O'Shaughnessy, MD
SCRI at Texas Oncology
